علاج ابيضاض الدم الليمفاوي الحاد مع كروموسوم فيلادلفيا (جين الدمج BCR::ABL1)

References

• About 25 percent of adults with ALL have a subtype called Philadelphia chromosome-positive ALL (also known as "Ph+ ALL" or "Ph-positive ALL").
• This chromosomal alteration creates a fusion gene called BCR::ABL1.
• Patients who have Ph+ ALL are typically treated with tyrosine kinase inhibitors (TKIs), combined with other medication, either chemotherapy or a steroid.
• TKIs typically used to treat Ph+ ALL include dasatinib (Sprycel®), imatinib (Gleevec®), or ponatinib (Iclusig®).
• Patients also receive CNS-directed therapy during treatment.
• For patients who cannot tolerate intensive chemotherapy, researchers are also studying TKI-based regimens with low-dose chemotherapy or chemotherapy-free treatments with blinatumomab and inotuzumab ozogamicin.